Spencer brings significant expertise with over 23 years in drug development and commercialization experience across large and small biotech. He has dedicated more than 12 years of his career to amyloid-related diseases, including AL and ATTR amyloidosis, Alzheimer’s and Parkinson's disease, and has authored over 30 scientific publications in amyloidosis.
Prior to Attralus, he was VP, Head of Global Strategy for ATTR Amyloidosis at Akcea and Ionis. Prior to that, he was VP, Head of Development Operations and Medical Affairs for Prothena Biosciences leading programs in AL and ATTR Amyloidosis. In addition, Spencer has significant leadership experience in clinical development, portfolio program management and as a Project Team Leader at Genentech, Elan, Janssen and Ultragenyx working to bring >15 new therapeutic candidates through IND, >10 to phase 3, and 6 products to the market.
Spencer has a BS in Neuroscience from Vanderbilt University, an MPH in Outcomes Research from Johns Hopkins School of Public Health, and an MBA from the Paul Merage School of Business at University of California.
Jonathan Wall is a Professor at University of Tennessee Medical Center, Knoxville and Head of the Amyloidosis and Cancer Theranostics Program. Jonathan is an internationally known expert in the field of amyloidosis, has worked in amyloid based research for over 20 years.
He has over 100 publications and more than 13 issued US patents in this field. His research work was instrumental in the development of multiple antibody-based therapeutics that have undergone clinical development by biotech companies. His lab has received over $10M in NIH grant and contract funding for work that focuses on the development and translation of novel diagnostic and therapeutic reagents for amyloidosis.
Benson has over 30 years of experience in financial and business development activities in life science companies. He is a consulting CFO to startups and has served as Interim CFO at E-Scape Bio, ReCode Therapeutics, and GABAeron. Prior to this, he served as CEO of Lapis Pharmaceutical as well as Senior VP Corporate Development at CoTherix where he was responsible for in-licensing Ventavis® (iloprost) which was later FDA approved and successfully launched.
Benson’s prior experience also includes being the first VP for venture debt lending at Imperial Bank/Comerica, serving as CFO at Cibus Pharmaceutical, Controller at Matrix Pharmaceuticals, and Division Controller in Express Banking at Wells Fargo Bank. He was also a tax accountant and CPA at Arthur Young & Co. after he received his BS in Biology from the University of Oregon. His responsibilities have included filing S-1s, equity and debt financing and product licensing.
Scott has more than 35 years of experience working in biotech and pharma, with deep expertise in CMC development and the manufacturing of a wide range of therapeutic product types including small molecules, hormones, and other therapeutic proteins, such as monoclonal and bispecific antibodies, oncolytic viruses, cytotoxic prodrugs, cancer vaccines, and therapeutic plasmids. Through his years of experience, Scott has served in senior executive roles managing CMC development and manufacturing operations as well as Regulatory Affairs, Quality, Project Management, and Product Development functions. He has facilitated the development of several products through preclinical and clinical development to commercialization.
Prior to joining Attralus, Scott served as Vice President of Technical Operations at Protein Design Labs; Senior Vice President, Head of Product Development at Onyx Pharmaceuticals; Vice President of Manufacturing and Process Development at BioMarin; Vice President of Technical Operations at Xencor; and Head of CMC at Bavarian Nordic. Scott earned an M.S. in Microbiology at Texas A&M University and a B.S. degree in Microbiology from University of Louisiana at Lafayette.